Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 217

1.

Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms.

Lanctôt KL, Amatniek J, Ancoli-Israel S, Arnold SE, Ballard C, Cohen-Mansfield J, Ismail Z, Lyketsos C, Miller DS, Musiek E, Osorio RS, Rosenberg PB, Satlin A, Steffens D, Tariot P, Bain LJ, Carrillo MC, Hendrix JA, Jurgens H, Boot B.

Alzheimers Dement (N Y). 2017 Aug 5;3(3):440-449. doi: 10.1016/j.trci.2017.07.001. eCollection 2017 Sep. Review.

2.

Euro-Esli: a European audit of real-world use of eslicarbazepine acetate as a treatment for partial-onset seizures.

Villanueva V, Holtkamp M, Delanty N, Rodriguez-Uranga J, McMurray R, Santagueda P.

J Neurol. 2017 Nov;264(11):2232-2248. doi: 10.1007/s00415-017-8618-5. Epub 2017 Sep 18.

3.

EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity.

Albu DI, Wang Z, Huang KC, Wu J, Twine N, Leacu S, Ingersoll C, Parent L, Lee W, Liu D, Wright-Michaud R, Kumar N, Kuznetsov G, Chen Q, Zheng W, Nomoto K, Woodall-Jappe M, Bao X.

Oncoimmunology. 2017 Jun 28;6(8):e1338239. doi: 10.1080/2162402X.2017.1338239. eCollection 2017.

4.

The Role of Disulfide Bond Replacements in Analogues of the Tarantula Toxin ProTx-II and Their Effects on Inhibition of the Voltage-Gated Sodium Ion Channel Nav1.7.

Wright ZVF, McCarthy S, Dickman R, Reyes FE, Sanchez-Martinez S, Cryar A, Kilford I, Hall A, Takle AK, Topf M, Gonen T, Thalassinos K, Tabor AB.

J Am Chem Soc. 2017 Sep 20;139(37):13063-13075. doi: 10.1021/jacs.7b06506. Epub 2017 Sep 7.

5.

Mitochondrial permeability transition pore: sensitivity to opening and mechanistic dependence on substrate availability.

Briston T, Roberts M, Lewis S, Powney B, M Staddon J, Szabadkai G, Duchen MR.

Sci Rep. 2017 Sep 5;7(1):10492. doi: 10.1038/s41598-017-10673-8.

6.

Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models.

Ito K, Hamamichi S, Abe T, Akagi T, Shirota H, Kawano S, Asano M, Asano O, Yokoi A, Matsui J, Umeda IO, Fujii H.

Cancer Sci. 2017 Nov;108(11):2273-2280. doi: 10.1111/cas.13392. Epub 2017 Sep 22.

7.

Diabetes Exacerbates Infection via Hyperinflammation by Signaling through TLR4 and RAGE.

Nielsen TB, Pantapalangkoor P, Yan J, Luna BM, Dekitani K, Bruhn K, Tan B, Junus J, Bonomo RA, Schmidt AM, Everson M, Duncanson F, Doherty TM, Lin L, Spellberg B.

MBio. 2017 Aug 22;8(4). pii: e00818-17. doi: 10.1128/mBio.00818-17.

8.

Evasion of immunosurveillance by genomic alterations of PPARγ/RXRα in bladder cancer.

Korpal M, Puyang X, Jeremy Wu Z, Seiler R, Furman C, Oo HZ, Seiler M, Irwin S, Subramanian V, Julie Joshi J, Wang CK, Rimkunas V, Tortora D, Yang H, Kumar N, Kuznetsov G, Matijevic M, Chow J, Kumar P, Zou J, Feala J, Corson L, Henry R, Selvaraj A, Davis A, Bloudoff K, Douglas J, Kiss B, Roberts M, Fazli L, Black PC, Fekkes P, Smith PG, Warmuth M, Yu L, Hao MH, Larsen N, Daugaard M, Zhu P.

Nat Commun. 2017 Jul 24;8(1):103. doi: 10.1038/s41467-017-00147-w.

9.

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial.

Kiyota N, Robinson B, Shah M, Hoff AO, Taylor MH, Li D, Dutcus CE, Lee EK, Kim SB, Tahara M.

Thyroid. 2017 Sep;27(9):1135-1141. doi: 10.1089/thy.2016.0549. Epub 2017 Aug 14.

10.

Eribulin shows high concentration and long retention in xenograft tumor tissues.

Sugawara M, Condon K, Liang E, DesJardins C, Schuck E, Kusano K, Lai WG.

Cancer Chemother Pharmacol. 2017 Aug;80(2):377-384. doi: 10.1007/s00280-017-3369-7. Epub 2017 Jun 29.

11.

Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.

Tamai T, Hayato S, Hojo S, Suzuki T, Okusaka T, Ikeda K, Kumada H.

J Clin Pharmacol. 2017 Sep;57(9):1138-1147. doi: 10.1002/jcph.917. Epub 2017 May 31.

12.

Evaluation of Quality of Life at Progression in Patients with Soft Tissue Sarcoma.

Hudgens S, Forsythe A, Kontoudis I, D'Adamo D, Bird A, Gelderblom H.

Sarcoma. 2017;2017:2372135. doi: 10.1155/2017/2372135. Epub 2017 Apr 23.

13.

Therapeutic Response to Twice-daily Rabeprazole on Health-related Quality of Life and Symptoms in Patients with Refractory Reflux Esophagitis: A Multicenter Observational Study.

Kinoshita Y, Hongo M, Kusano M, Furuhata Y, Miyagishi H, Ikeuchi S; RPZ Study Group.

Intern Med. 2017;56(10):1131-1139. doi: 10.2169/internalmedicine.56.7896. Epub 2017 May 15.

14.

The Toll-Like Receptor 4 Antagonist Eritoran Protects Mice from Lethal Filovirus Challenge.

Younan P, Ramanathan P, Graber J, Gusovsky F, Bukreyev A.

MBio. 2017 Apr 25;8(2). pii: e00226-17. doi: 10.1128/mBio.00226-17.

15.

Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study.

Smith SR, Garvey WT, Greenway FL, Zhou S, Fain R, Pilson R, Fujioka K, Aronne LJ.

Obesity (Silver Spring). 2017 May;25(5):857-865. doi: 10.1002/oby.21811.

16.

Lenvatinib for Anaplastic Thyroid Cancer.

Tahara M, Kiyota N, Yamazaki T, Chayahara N, Nakano K, Inagaki L, Toda K, Enokida T, Minami H, Imamura Y, Sasaki T, Suzuki T, Fujino K, Dutcus CE, Takahashi S.

Front Oncol. 2017 Mar 1;7:25. doi: 10.3389/fonc.2017.00025. eCollection 2017.

17.

Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes.

Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, Dutcus CE, Teng A, Gianoukakis AG, Sherman SI.

Endocrine. 2017 Apr;56(1):121-128. doi: 10.1007/s12020-017-1233-5. Epub 2017 Feb 3.

18.

Targeting of tumor growth and angiogenesis underlies the enhanced antitumor activity of lenvatinib in combination with everolimus.

Matsuki M, Adachi Y, Ozawa Y, Kimura T, Hoshi T, Okamoto K, Tohyama O, Mitsuhashi K, Yamaguchi A, Matsui J, Funahashi Y.

Cancer Sci. 2017 Apr;108(4):763-771. doi: 10.1111/cas.13169. Epub 2017 Apr 20.

19.

Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JSNP Working Group Report.

Suhara T, Chaki S, Kimura H, Furusawa M, Matsumoto M, Ogura H, Negishi T, Saijo T, Higuchi M, Omura T, Watanabe R, Miyoshi S, Nakatani N, Yamamoto N, Liou SY, Takado Y, Maeda J, Okamoto Y, Okubo Y, Yamada M, Ito H, Walton NM, Yamawaki S.

Int J Neuropsychopharmacol. 2017 Apr 1;20(4):285-294. doi: 10.1093/ijnp/pyw111. Review.

20.

Supplemental Content

Loading ...
Support Center